<DOC>
	<DOC>NCT01954394</DOC>
	<brief_summary>Primary Objective: To assess the long-term safety of alirocumab when added to lipid-lowering therapy in patients with heterozygous familial hypercholesterolemia (heFH). Secondary Objectives: To evaluate the long-term efficacy of alirocumab on lipid parameters. To evaluate the long-term immunogenicity of alirocumab.</brief_summary>
	<brief_title>Open Label Study of Long Term Safety Evaluation of Alirocumab</brief_title>
	<detailed_description>The maximum study duration will be 176 weeks per patient.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Patients with heFH who have completed one of the four parent studies (EFC12492, R727CL1112, EFC12732 and LTS11717). Exclusion criteria: Significant protocol deviation in the parent study; Any permanent treatment discontinuation from the parent study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>